With FDA approval, Genentech turns eye implant's focus to diabetes
Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against the other stocks ...
pharmaphorum1d
Regeneron and Alnylam seek RNAi therapies for NASH
Regeneron and Alnylam are to research treatments ... and is associated with increased risk of problems such as diabetes, heart attacks, and strokes. Drugs that get to market could generate ...
Nasdaq3d
Regeneron Reports Positive Three-Year Results for EYLEA HD Treatment in Wet Age-Related Macular Degeneration
Regeneron Pharmaceuticals announced positive ... in the retina often caused by poor blood sugar control in people with diabetes. The disease generally starts as nonproliferative diabetic ...
Long Island Press15d
Four Nassau students named Regeneron finalists
Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron Science Talent Search.
Long Island Press27d
MacArthur High School senior named Regeneron semifinalist
General Douglas MacArthur High School senior Melody Hong has been named one of 300 semifinalists in the 2025 Regeneron Science ... as Alzheimer’s and Type 1 diabetes. Through her innovative ...